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Abstract
Background: Subclinical atherosclerosis may result in fatal cardiovascular (CV) events, but the underlying
mechanisms and molecular players leading to disease are not entirely understood. Thus, novel approaches capable
of identifying the factors involved in pathological progression and providing a better understanding of the
subjacent mechanisms are needed. Extracellular vesicles (EVs) have been shown to have numerous biological
functions, and their metabolome has recently generated interest as a source of novel biomarkers. The metabolic
content of the exosomes has been so far unexplored in cardiovascular disease (CVD), and here, we developed an
analytical strategy aimed at probing urinary exosomal metabolite content and its association to CV risk.
Results: Direct analysis of the exosomes without metabolite extraction was evaluated by high-resolution magic
angle spinning (1H HR-MAS). Other two methodologies for the analysis of exosomal metabolites by 1H NMR were
set up, based on methanol or organic solvents sequential extraction. The three methods were compared in terms
of the number of detected signals and signal to noise ratio (S/N). The methanol method was applied to identify
altered metabolites in the urinary exosomes of subjects with programmed coronary artery by-pass grafting (CABG)
versus a control group. Target mass spectrometry (MS) was also performed for differential analysis. The clinical
performance of exosomal metabolites of interest in CVD was investigated, and the added value of the exosomes
compared to urine analysis was evaluated.
Based on S/N ratio, simplicity, reproducibility, and quality of the spectrum, the methanol method was chosen for the
study in CVD. A cardiometabolic signature composed by 4-aminohippuric acid, N-1-methylnicotinamide, and citric acid
was identified in urinary exosomes. Directly in urine, 4-aminohippuric acid and citric acid do not show variation
between groups and changes in N-1-methylnicotinamide are less pronounced, proving the added value of exosomes.
Conclusions: We set up a novel methodology to analyze metabolic alterations in urinary exosomes and
identified a cardiometabolic signature in these microvesicles. This study constitutes the first evidence of a role
for the exosomal metabolism in CVD and demonstrates the possibility to evaluate the urinary exosomal
metabolic content by NMR and MS.
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Background
Despite the knowledge of traditional risk factors and the
enormous efforts dedicated to improve prevention,
cardiovascular disease (CVD) remains the leading cause
of death worldwide [1]. Subjacent mechanisms involve
multiple factors and acting molecules playing together in
a complex network which is not fully understood. Thus,
further knowledge of these acting molecules is needed.
The metabolome represents the ultimate response of the
organism to a pathophysiological condition, and the
metabolites are the molecules most closely reflecting the
cell phenotype. In CVD, specific metabolites have been
identified in biological fluids [2–4], whole arterial tissue
[5], and arterial layers at their specific location [6].
Extracellular vesicles (EVs) constitute an additional
source of information. They act as biological messengers
in cell-to-cell communication, RNA and protein transfer,
and immune response regulation [7, 8], with a growing
interest in their potential role as a therapeutic tool in tis-
sue regeneration and as a way for drug delivery [9]. We
have previously showed how urinary exosomes reflect
protein changes taking place in the kidney in diabetic
nephropathy, constituting an accessible source of infor-
mation complementary to renal biopsy [10] and more
recently in hypertensives developing albuminuria as a
main CV risk factor [11]. However, the metabolome of
EVs is a new focus of interest since very recently, mainly
in cancer, to investigate inter-cellular communication or
novel biomarkers if present in EVs isolated from bio-
logical fluids [12–14]. In CVD, the EV metabolism has
been so far unexplored.
Following previous studies by our group using nuclear
magnetic resonance (NMR) applied to CVD and renal
disease [5, 15–18], we aimed first to develop for the first
time a methodological approach to analyze the urinary
exosome metabolome by NMR also compatible with LC-
MS analysis. Then, we aimed to investigate the metabo-
lome of urinary exosomes in CVD, particularly in
patients undergoing coronary artery by-pass grafting
(CABG) as representative population of high CV risk.
Three different protocols were set up and compared,
two of them based on metabolite extraction from urinary
exosomes and a third one consisting in direct analysis of
the exosomal pellet. The best-performing method was
then applied as a screening methodology to investigate
differences in patients with high CV risk. Selected me-
tabolites were further analyzed by target mass spectrom-
etry (MS) in selected reaction monitoring mode (SRM).
Their potential in the clinic was assessed, and their
added value to whole urine analysis in CVD evaluated.
Results
Direct analysis of the exosomal pellet by 1H HR-MAS
versus metabolite extraction and NMR analysis
Urinary exosomes were isolated by ultracentrifugation.
The replacement of the sucrose solution by PBS assures
the exosomal integrity while eliminating sucrose inter-
ference in the NMR spectrum. Figure 1 shows Western
blot analysis of the well-known exosomal markers Alix
and TSG101 and an electron microscopy image of a
representative urinary exosome preparation obtained
with the protocol herein described.
To set up a protocol for the analysis of the exosomal
metabolites by 1H NMR, we first optimized the extrac-
tion of the metabolites from the exosomal pellet to the
liquid phase. On the one hand, a methanol-based extrac-
tion was performed, and on the other hand, a sequential
extraction in organic solvents of decreasing polarity was
performed (chloroform-based method). Additionally, we
analyzed the exosomal pellet without metabolite extrac-
tion by 1H HR-MAS, testing the potential of this tech-
nique for the direct analysis of the isolated exosomes.
Figure 2 shows the representative spectra obtained for
the two extraction methods (methanol-based and
chloroform-based) and for the direct analysis of the exo-
somal pellet (non-extraction method). The high intensity
signal of chloroform (7.7 ppm) can be clearly seen, thus
being a potential mask of lower-abundance metabolites
of interest in the aromatic area of the spectra.
Fig. 1 Characterization of urinary exosomes isolated from urine. a Western blot of Alix. b Western blot of TSG101. c Electron microscopy image.
Two exosomal fractions (EX) from two different healthy controls (EX1 and EX2) were analyzed and compared to urine
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In an attempt to characterize each of these methods
individually and estimate which metabolite classes are
favored in each of them, the total number of detected
peaks was calculated per method and spectral region
and classified according to their intensity range (low,
medium, or high) (Additional file 1: Fig. S1). For the
three protocols, the highest number of detected peaks
and of “high intensity” peaks are in the upfield area (0–
5 ppm), while the “low intensity” peaks are grouped
mainly in the aromatic and vinylic area, i.e., in the region
from 5 to 10 ppm or downfield area, where the number
of peaks is significantly lower than in the upfield. Be-
sides, the number of detected peaks was calculated with
different sensitivity cut-off values, i.e., 3, 5, 8, and 10
times the S/N value (Additional file 2: Fig. S2). 1H HR-
MAS method resulted in the highest number of detected
peaks with intensity values higher than 3 times S/N.
However, if this cut-off value was increased, the sensitiv-
ity deeply and proportionally diminished (from 96
detected peaks to 64 when peak intensity cut-off value
was 3 or 10 times S/N, respectively). The methanolic
extraction resulted in a more constant sensitivity (from
Fig. 2 Evaluation of the three methodological approaches developed for the analysis of the exosomal metabolome. The three spectra corresponding
to methanolic extraction (1H NMR), organic solvent extraction (1H NMR), and direct analysis of the exosomal pellet (without extraction) (1H HR-MAS)
are shown overlaid. 1H HR-MAS spectrum was scaled by a factor of 0.1301 for proper visual comparison matching the noise level
Fig. 3 Average S/N values obtained for each region of the spectrum and calculated including all peaks detected by the three methods
(methanol-based extraction, chloroform-based extraction, or direct analysis by 1H HR-MAS). *p value = 0.0185. The number of common signals per
region was 8 signals (0–2 ppm), 5 signals (1.5–2.5 ppm), 19 signals (2.5–4.5 ppm), 29 signals (0.5–5 ppm), and 10 signals (6.5–8.5 ppm)
Agudiez et al. BMC Biology          (2020) 18:192 Page 3 of 9
76 detected peaks to 67, in the same range). To estimate
the sensitivity of each method, the average S/N was
calculated for all common peaks (those detected by the
3 methods), resulting in a lower S/N ratio in all regions
when the exosomal pellet was directly analyzed by 1H
HR-MAS (Fig. 3).
In view of these data, its simplicity, and the lack of
interference from solvents as chloroform, we chose the
methanol method to investigate a role of the urinary
exosomal metabolites in CVD after a proper reproduci-
bility evaluation. One spot urine was divided into five
aliquots and individually and equally processed to firstly
isolate the exosomal fraction and then perform the
metabolite extraction from each of the five exosomal
pellets obtained, individually. Metabolite extracts from
the five replicates were then analyzed by 1H NMR.
The high reproducibility of the method can be seen
in Additional file 3: Fig. S3, showing the five spectra
obtained. The average number of peaks was 110 (93–132)
(minimum-maximum) with a coefficient of variation of
13%. No significant difference was observed in peak inten-
sity among the replicates (p value = 0.2451).
Identification of a cardiometabolic signature in urinary
exosomes: what exosomes add to urine analysis
With the aim of investigating a potential role for the
metabolic content of urinary exosomal fraction in CVD,
we recruited patients with programmed CABG as the
CV risk group, and healthy donors without CV risk
factors (hypertension, diabetes, or CVD previously docu-
mented, being that myocardial infarction, angina, or car-
diac insufficiency). Clinical data are compiled in Table 1.
Urine was collected, exosomes were isolated as de-
scribed, and the metabolites were extracted following
the methanol protocol. Metabolic exosomal extracts
were analyzed by 1H NMR. Once isolated from urine,
the exosomal pellets were weighted, resulting in no signifi-
cant differences between the CV risk and control groups
(Mann-Whitney non-parametric test, p value = 0.9840).
Partial least square discriminant analysis (PLS-DA) of the
exosomal metabolome shows good separation between
the two study groups (Additional file 4: Fig. S4).
Additional file 5: Table S1 shows those chemical shifts
found with significant variation (p value < 0.05) and fur-
ther analyzed by target MS (Additional file 6: Table S2).
An exosomal metabolic fingerprint associated with CV
risk was identified composed by 4-aminohippuric acid, N-
1-methylnicotinamide, and citric acid. As can be seen in
Fig. 4, 4-aminohippuric acid was found increased in the
CV risk group, whereas citric acid and N-1-
methylnicotinamide showed lower levels in that group. A
permutation test confirmed the statistical significance for
the three metabolites, resulting in p value < 0.0001 for N-
1-methylnicotinamide and citric acid and p value = 0.0045
for 4-aminohippuric acid. To evaluate the clinical utility in
terms of sensitivity and specificity, a combined ROC curve
was calculated. Figure 4 shows the ROC resulting when
the three metabolites (4-aminohippuric acid, N-1-
methylnicotinamide, and citric acid) are considered.
To evaluate if the exosomes have added value to urine
also at the metabolome level, we analyzed the identified
metabolites directly in the urine of the same CABG
patients (CV risk group) and control individuals by
target MS. As can be seen in Fig. 5, 4-aminohippuric
acid does not show variation between groups, contrary
to what was observed when analyzed in the exosomal
fraction. Citric acid tends to diminish but without
significance, and the change in N-1-methylnicotinamide
is less pronounced in urine than the one observed in the
exosomes proving, thus, the added value of study urine
exosomal metabolome.
Discussion
CVD accounts for more than 30% of all global deaths.
Despite enormous efforts on prevention, further research
and novel indicators of CV risk are needed. Complemen-
tary to biological fluids, exosomes reflect molecular al-
terations that otherwise would be masked if measured
directly in the biological fluids of origin. Their role as
biomarker source or biological messengers in inter- and
intracellular communication has been also evidenced
[19]. Particularly, their study in CVD is gaining interest
[20–23] but, to the best of our knowledge, there is no
previous evidence on their metabolic content in this
clinical context.
Up to date, the metabolome of the urinary exosomes
is underexplored. There are only two studies on the
metabolic analysis of urinary exosomes [24, 25], both by
target LC-MS/MS and in prostate cancer. This study
represents the first report of the analysis of the urinary
exosomal metabolites by NMR and furthermore pro-
poses a methodology compatible with both, NMR and
LC-MS. Also, this is the first evidence of exosome meta-
bolic alterations in CVD.
Table 1 Clinical data of control subjects and patients
undergoing coronary artery by-pass grafting (CABG) included in
the study. PVD peripheral vascular disease
Control subjects CABG patients
Age 49 ± 6 68 ± 9
Sex (% male) 43 52
Diabetes (%) 0 26
Hypertension (%) 0 89
Previous coronary event (%) 0 56
Dyslipidemia 0 78
PVD 0 15
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The comparison between extraction methods (metha-
nol-based and chloroform-based) and non-extraction
method (1H HR-MAS) shows higher S/N when the
metabolites are extracted to liquid phase, which may be
a consequence of the removal of interference com-
pounds affecting 1H HR-MAS spectrum (e.g., lipids).
Both extraction methods perform similarly in the high-
field region (0–5 ppm), and the aromatic area is specially
favored from the extraction procedure, particularly in
the chloroform-based method. However, the chloroform
itself constitutes an interference in that area, thus limit-
ing the beneficial of chloroform-based extraction.
Three metabolites were identified in urinary exosomes
from CV risk patients with an altered pattern compared
to healthy individuals: 4-aminohippuric acid, N-1-
methylnicotinamide, and citric acid. In atherosclerosis
development, excess reactive oxygen species (ROS)
causes arterial wall remodeling with smooth muscle cell
proliferation and increased inflammation [26]. In our
cohort of CV risk patients, increased production of ROS
is expected. Higher levels of 4-aminohippuric acid found
in these patients are in agreement with increased levels
of this metabolite previously reported in conditions of
higher ROS production and enhanced inflammatory
response [27]. N-1-Methylnicotinamide has vasorelaxat-
ing properties and may exert antithrombotic and anti-
inflammatory effects [28, 29]. Decreased levels found
here in CV risk patients are in accordance with a poten-
tial protective role in the arterial wall, serving as a
molecular indicator of atherosclerosis development.
Our group previously reported tricarboxylic acid (TCA)
cycle metabolic deregulation in hypertensive individuals
of higher CV risk, e.g., albuminuria development or re-
sistant hypertension [17]. Here, reduced levels of citric
acid were found in CV risk patients, following the same
trend previously observed in chronic kidney disease
(CKD) versus healthy subjects with aggravated trend in
those CKD patients with CVD [18].
One limitation of the study is the limited number of
patients and control subjects included, which may com-
promise the conclusions due to unrelated sources of
variation. Further studies should follow in wider cohorts
for additional validation.
Fig. 4 Target mass spectrometry analysis of exosomal metabolites showing variation between control subjects (n = 14) and CV risk patients (pre-
CABG) (n = 18): 4-aminohippuric acid, citric acid, and N-1-methylnicotinamide. Receiver operating curve (ROC) resulting when the three
metabolites are combined is shown. The Mann-Whitney test with 95% confidence level was applied. CABG coronary artery by-pass grafting. ***p
value < 0.001, ****p value < 0.0001
Fig. 5 Target mass spectrometry analysis of urine metabolites in control (n = 24) and CV risk (n = 26) groups: 4-aminohippuric acid, citric acid, and
N-1-methylnicotinamide. The Mann-Whitney test with 95% confidence level was applied. CABG coronary artery by-pass grafting. *p value < 0.05
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Conclusions
A novel methodology to investigate metabolic alterations
in urine at the exosomal level has been developed for
NMR, compatible with LC-MS/MS analysis, and suc-
cessfully applied here to clinical samples. This study
constitutes the first evidence of a role for the exosomal
metabolism in CVD and opens a new field of research in
other pathologies. An exosomal metabolic signature
linked to CVD was identified, confirming the existence
of specific metabolite deregulation in urinary exosomes
demonstrating the added value of extracellular vesicles
in biomarker research.
Methods
Patient recruitment and urine collection
Human urine samples were collected in sterile con-
tainers and immediately transported to the laboratory.
For exosome analysis, a minimum volume of 50 mL
urine was collected and protease inhibitors cocktail was
added (Sigma P8340). For urine metabolome analysis, 1
mL was centrifuged (16,200g, 10 min, 4 °C) and the
supernatant was collected. Samples were stored at −
80 °C until analysis. A total of 27 patients undergoing
coronary artery by-pass grafting (CABG) at Fundación
Jiménez Díaz Hospital (Madrid, Spain) and 28 healthy
subjects from the Donation Unit at the same hospital
were recruited. The study was conducted according to
the recommendations of the Declaration of Helsinki and
was approved by the local ethics committee (PIC51-
2013). In all cases, informed consent was requested indi-
cating that their participation in the study was not preju-
dicial in any way to the treatment and possesses no risk.
Urinary exosome isolation and characterization
Ultracentrifugation remains a mainstay for biomarker
discovery in EVs [30, 31]. The exosome-like fraction
(here referred as exosomes) was obtained from urine by
modifying and adapting a previously published protocol
[10, 11, 32]. Urine samples were defrosted and vigor-
ously vortexed. Then, samples were centrifuged (17,
000g, 10 min, 4 °C) to remove cell debris and the super-
natant was collected. The pellet was treated with 200
mg/mL dithiothreitol (DTT) in PBS (150 mM NaCl,
12.5 mM Na2HPO4, 11.5 mM NaH2PO4, in ddH2O, pH
7.2), instead of isolation solution as previously published,
and heated at 37 °C for 10 min in order to reduce
Tamm-Horsfall protein (THP) networks and release
trapped exosomes [33]. Then, 10 mL of PBS was added
and a new low-speed centrifugation (17,000g, 10 min)
was performed. Following centrifugation, the resulting
supernatant was collected, mixed with the one obtained
from the first centrifugation step, and finally ultracentri-
fuged (175,000g, 70 min, 4 °C) to pellet the exosomes.
These modifications make the exosomes compatible
with subsequent NMR and LC-MS analyses.
Isolated exosomes were characterized by electron mi-
croscopy by suspension in 4% paraformaldehyde in PBS
and spotted on parafilm. A Formvar-carbon-coated grid
(Ted Pella Inc. CA-USA) was floated on the sample
droplet for 3 min and then on a drop of ddH20 for 1
min. To obtain the contrast of the samples, a negative
stain was carried out by floating the grid on a drop of
2% uranyl acetate in ddH20 for 30 s. The excess fluid
was removed, and the results were visualized using a
JEM 1010 transmission microscope (JEOL Peabody, MA,
USA). Additionally, exosomes were characterized by
Western blot with primary antibodies Alix (1:500, Santa
Cruz; (1A12) SC-53540 Lot: K1115) and TSG-101 (1:
500, Abcam; [4A10] (ab83) Lot: GR3218062-2). Rabbit
anti-mouse-HRP (1:2500, Santa Cruz) was used as a
secondary antibody.
Metabolite extraction from urinary exosomes
For metabolite extraction from urinary exosomes, two
protocols were set up and compared. The first one was
based on and improved from a protocol previously
applied in the laboratory to aortic tissue [5]. The exoso-
mal pellet was solubilized in 600 μL of cold methanol
(MeOH):H2O (1:1), vigorously vortexed, and sonicated
for 30 min at 4 °C. The samples were then centrifuged,
and the supernatant was collected. The second protocol,
described to extract metabolites from exosomes isolated
from plasma and culture media [34], was here adapted
and modified accordingly to be tested in urinary exo-
somes. For that, the exosome pellet was solubilized in
200 μL of ddH2O, left on ice for 30 s, heated at 37 °C for
90 s, and sonicated at 4 °C for 30 s. Then, 200 μL of cold
MeOH was added followed by 200 μL of chloroform,
and samples were centrifuged (16,200g, 10 min, 4 °C).
The supernatant was transferred to a new tube, and
200 μL of acetonitrile (ACN) was added. Samples were
incubated for half an hour at 4 °C and centrifuged, and
the supernatant was stored at − 20 °C until further
analysis.
1H HR-MAS analysis of metabolites from intact exosomal
fraction: spectra acquisition
High-resolution magic angle spinning (1H HR-MAS) is a
non-destructive technique which allows direct measure
on tissue without extracting the metabolites. We tested
it by direct analysis of the exosomal pellet without
solubilization and operating at 4 °C to avoid sample deg-
radation. 1H HR-MAS spectroscopy was performed at
500.13MHz using a Bruker AVIII500 spectrometer 11.7
T. Samples were placed within a 50-μL zirconium oxide
rotor with cylindrical insert and spun at 5000-Hz spin-
ning rate, to remove the effects of spinning side bands
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from the spectra acquired. Standard solvent suppressed
spectra were acquired into 32 k data points, averaged
over 512 acquisitions, using a sequence based on the
first increment of the NOESY pulse sequence. A spectral
width of 6009 Hz was used.
A Carr-Purcell-Meibom-Gill (CPMG) pulse sequence
was used as a T2 filter to suppress broad signals from
macromolecules, so permitting the identification of small
metabolites. Water suppression was achieved through
irradiation of water signal during 2 s. The following
parameters were used: 512 scans, a spectral width of
6009 Hz, and 32 k data points. Spectra were processed
using TOPSPIN software, version 3.5 (Bruker Rheinstetten,
Germany). Spectra were phased, baseline-corrected, and
referenced to the TSP singlet at δ 0 ppm.
1H NMR analysis of extracted exosomal metabolites:
spectrum acquisition
The supernatant containing the exosomal metabolites was
speed-vacuum dried, and the resulting pellet was resus-
pended in 100mM sodium phosphate buffer containing
0.01mM sodium (3-trimethylsilyl)-2,2,3,3-tetradeuterio-
propionate (TSP) for chemical shift referencing. The use
of PBS in exosome isolation instead of other solvents or
solutions is key for the compatibility with NMR approach.
All NMR experiments were performed at 278 K on a
Bruker 700-MHz AVANCE III instrument operating at
700.17MHz equipped with a 5-mm triple resonance cryo-
probe with a z-axis gradient. NMR spectra were acquired
using a standard pulse sequence noesypr1d with water
suppression during relaxation time 2 s, the acquisition
time was 1.45 s, and the mixing time was 150ms. The
number of scans was 512 and a 90° pulse set to 14 μs,
using 32 k data points with a spectral width of 16 ppm.
Line broadening at 1 Hz was applied before Fourier trans-
formation. All spectra were manually phased, baseline-
corrected, and calibrated to TSP (δ 0.00 ppm) with Top-
Spin 3.2 (Bruker, Rheinstetten, Germany).
Method performance comparison
Peak peaking and S/N calculation were performed by
ACDLabs software, version 2019.1, and TopSpin
software, version 3.5 (Bruker, Rheinstetten, Germany).
Considering these data, statistical analysis using Graph-
Pad Prism 6 software was performed to compare the
three set-up protocols to study the exosome metabo-
lome by NMR. To characterize the resultant spectra
from the three methods, peak intensities recorded for
each of them were classified in quartiles as follows: “high
intensity” peaks, with intensity higher than the 3rd
quartile cut-off value (≥ 75% of maximum intensity);
“low intensity” peaks, with intensity lower than the 1st
quartile cut-off value (≤ 25% of maximum intensity); and
“medium intensity” peaks for those with intensity in
between. Additionally, the average signal to noise ratio
(S/N) was calculated, considering those peaks detected
in the three methods with a S/N > 3. Finally, the robust-
ness of the selected method (reproducibility) was further
evaluated by analyzing five replicates (non-parametric
Kruskal-Wallis test).
Screening of exosomal metabolites showing alteration in
CV risk patients by NMR
NMR spectra were analyzed using AMIX software (version
3.9.15, Bruker Rheinstetten, Germany). Each spectrum,
from 0.5 to 10.00 ppm, was partitioned into equally sized
spectral regions of 0.04 ppm (buckets) which were individu-
ally integrated by summing up the intensities of every ex-
perimental point inside each bucket. For normalization,
individual bucket integrals so obtained were scaled by div-
iding their values by the total spectral integral, once exclud-
ing the water resonance region (4.75–5.25 ppm). As a first
screening method, distribution of every bucket variable over
the ensemble of spectra was evaluated by AMIX software.
By Metaboanalyst 4.0 public web server [35], partial least
square discriminant analysis (PLS-DA) was performed fol-
lowing normalization (90% confidence level, scaled to unit
variance). Chemical shifts with fold change between clinical
groups ≥ 3 and p value < 0.05 were selected. Metabolite an-
notations were carried out by using Chenomx NMR Suite
8.3 profiler (Chenomx NMR Suit 2017, Edmonton, Canada)
and the HMBD database version 4.0 [36]. 2D NMR analysis
was carried out to confirm the annotations by homonuclear
correlation spectroscopy 1H–1H (COSY) and heteronuclear
single-quantum correlation spectroscopy 1H–13C (HSQC).
Exosomal metabolites target analysis by mass
spectrometry
Exosomal metabolites with potential variation between
CABG patients and healthy subjects were further
analyzed by target mass spectrometry in SRM mode,
coupled to liquid chromatography (SRM-LC-MS/MS)
[5, 15]. In SRM, a specific precursor and its correspondent
fragment ion (transition) were measured for every metab-
olite (Supplementary Table 2), previously determined by
direct infusion of commercial standards. We used a 6460
Triple Quadrupole LC-MS/MS (1200 Series, Agilent
Technologies) controlled by Mass Hunter Software (v4.0
Agilent Technologies). In a first quadrupole (Q1), the me-
tabolite precursor is selected and, following fragmentation
in Q2, the most intense fragment is selected in Q3. In this
way, specific transitions (precursor --> fragment) were an-
alyzed to quantify the metabolites of interest.
Metabolite extracts were speed-vacuum dried, and the
metabolites were solved in 50% cold methanol, filtered
(0.22 μm), and directly analyzed on an Atlantis T3
column (Waters) thermostatically controlled at 40 °C. A
sample volume of 10 μL was injected and separation
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took place at 0.4 mL/min in an acetonitrile gradient: (1)
at 0 min 0% B (0.1% formic acid in acetonitrile), (2) at 1
min 0% B, (3) at 2.5 min 95% B, (4) at 2.51 min 0% B,
and (5) at 5 min 0% B. Dwell time was fixed to 50 ms
and delta EMV to 400 V in positive mode and 600 V in
negative one. Collision energy and fragmentor potential
in the range 60–175 V were optimized for each metabol-
ite by analyzing commercial metabolite standards in the
previous set-up analysis. Additionally, to evaluate the
complementary value of urinary exosome metabolome,
urine analysis of those metabolites was performed fol-
lowing the same analytical conditions; urine proteins
were removed by organic precipitation, and the super-
natant was collected for analysis by SRM-LC-MS/MS.
To avoid potential bias in the exosomal recovery, the
final pellets were weighted for every subject, and peak
area values were normalized by the pellet weight. For
urine analysis, metabolite signals were normalized by
urinary creatinine (mg/dL). Groups were compared by
non-parametric Mann-Whitney test with 95% confi-
dence level (GraphPad Prism 6 software). The ROUT
method was applied to detect outliers based on the false
discovery rate, setting the Q value to 5%. Receiver oper-
ating characteristic (ROC) curves were calculated by
means of Metaboanalyst web server (version 4.0) [35].
ROC curves were generated by Monte-Carlo cross-
validation (MCCV) using balanced subsampling. In each
MCCV, two thirds (2/3) of the samples are used to
evaluate the feature importance. The top important fea-
tures are then used to build classification models which
are validated on 1/3 of the samples that were left out.
This procedure was repeated multiple times to calculate
the performance and confidence interval of each model.
Random Forests was selected as the classification
method and feature ranking built-in method.
To further confirm the statistical significance of the
exosomal metabolites, a permutation test was performed.
The null hypothesis that there is no difference between
patients and controls was simulated 10,000 times. For
each of these simulated samples, the difference between
the medians of patients and controls was calculated. Fi-
nally, the proportion of these 10,000 differences that ex-
ceeds the difference of the original sample was taken
out, and it was multiplied by two to make the test
bilateral.
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